VJHemOnc is committed to improving our service to you

VJVirtual | Improving outcomes of Ph-positive ALL patients with TKIs

VJHemOnc is committed to improving our service to you

Robin Foà

Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses advances in the treatment of adult patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). Ph-positive ALL represents the most frequent genetic subgroup within ALL in adults, increases in prevalence with age, and historically has been associated with a poor prognosis. Prof. Foà evaluates early treatment approaches used for this patient population, including intensive chemotherapy and transplantation as well as the efforts of the GIMEMA cooperative trial group who, 15 years ago, began using the tyrosine kinase inhibitor (TKI), imatinib, in elderly patients with Ph-positive ALL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter